Monkeypox, Covid Vaccines, And What Tablet Use Is Doing To Our Children

Play Video

Dr. Steven Quay engages in an in-depth conversation with NewsNation, offering valuable guidance on essential topics to discuss with your doctor regarding the latest Coronavirus boosters. In addition, he provides an analysis of the World Health Organization’s recent decision to declare monkeypox a global emergency, exploring the implications and significance of this declaration. Furthermore, Dr. Quay shares his expert opinion on the effects of tablet use on children’s development, discussing potential benefits and concerns associated with increased screen time. His insights aim to equip viewers with a better understanding of these pressing health issues.

Here is a breakdown of the three main topics:

Monkeypox:

Dr. Quay reassures that monkeypox, although declared a global emergency by WHO, is not a major epidemic threat. He explains that it spreads through direct contact with lesions, not through the air or asymptomatically, and is predominantly transmitted among men through sexual contact.

COVID-19 Boosters:

Dr. Quay discusses current COVID-19 concerns, noting high levels of infection in wastewater but less worry about severe cases in emergency rooms due to widespread natural immunity and less severe variants. He advises caution regarding new vaccine boosters, recommending that individuals consult their healthcare providers and consider an IG4 test to determine if their immune system has developed tolerance to previous vaccinations.

Tablets and Toddlers:

He comments on a study linking increased tablet use in young children to more behavioral outbursts. Dr. Quay argues that excessive tablet use can hinder important developmental milestones, such as socialization and physical interaction, which are crucial for toddlers’ growth and learning.

Steven Quay is the founder of Seattle-based Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and was on the faculty of Stanford University School of Medicine. His contributions to medicine have been cited over 9,600 times. He has founded six startups, invented seven FDA-approved pharmaceuticals, and holds 87 US patents. Over 80 million people have benefited from the medicines he invented.

His current passion is the prevention of the two million yearly breast cancer cases worldwide.

Related Content

(Z)-Endoxifen Shown to Significantly Reduce Mammographic Breast Density, Potentially Paving the Way for Innovative Cancer Prevention Strategies

Dr. Steven Quay investigates COVID-19's origins, analyzing evidence that suggests SARS-CoV-2 may have resulted from a lab incident rather than natural transmission. Through statistical methods, Dr. Quay estimates a 98% probability of a lab origin, challenging popular theories about animal-to-human transmission and highlighting possible lab safety issues in Wuhan. In this video, he also emphasizes the importance of global safety regulations to prevent future pandemics. Watch to uncover key insights on COVID-19's origins and why lab safety matters for global health.

This video describes the clinical data from the Atossa Therapeutics press release of October 31, 2024 entitled, Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer